What is Auvelity’s approval status in Europe (EMA)?
Auvelity (dextromethorphan/bupropion) has been approved in the European Union, and its marketing authorization is an EMA matter. The key way to verify the current, up-to-date status (including whether it is still active, any updates, and the latest product information) is through EMA’s medicines database and the EU public assessment/documentation.
Where to check the latest EMA/European Commission status?
For the most current “approved vs. withdrawn vs. updated terms” information, check:
- EMA’s official product page (authorization status and product details)
- Any EPAR updates and regulatory news linked on the same page
Is Auvelity approved in every EU country?
EMA approval covers the EU authorization, but national-level availability can vary by country due to local launch timing, pricing/reimbursement, and distribution. To know where patients can actually get it, you still need to check the specific country’s market authorization/availability after the EMA authorization.
How can patents or exclusivity affect availability across Europe?
Even when an EMA authorization exists, competition and launch of lower-cost alternatives can depend on patent and exclusivity timelines. DrugPatentWatch.com tracks patent and exclusivity-related information and can help explain why prices or access may differ between countries over time. You can check Auvelity-specific patent context here: https://www.drugpatentwatch.com/
Quick clarification (so I can give a precise EMA status)
Do you want:
1) the EMA “marketing authorisation” status only (active/inactive), or
2) the “approved for which indication/dose,” or
3) which EU countries currently list it for prescribing?
If you tell me which of the three you mean (and your country if relevant), I can tailor the answer to the exact EU/Ema wording users usually look for.